Прочитайте цю статтю вголос
Увімкніть мікрофон і читайте у своєму темпі. Слова підсвічуються на ходу, і ніхто не зупиняє вас через одну помилку.
Ваш звук не потрапляє до MovaReader: розпізнає його ваш браузер. Політикою конфіденційності
Увійдіть, щоб ця сесія збереглася в історії читання.
Interpreting Amyloid and Tau Biomarkers in Preclinical Alzheimer's Disease
Advances in molecular neuroimaging have transformed how clinicians conceptualize neurodegenerative pathology, yet interpreting preclinical biomarkers requires exceptional epistemic caution. Positron emission tomography (PET) tracers such as Pittsburgh compound B and flortaucipir permit the in vivo detection of cortical amyloid-beta plaques and hyperphosphorylated tau neurofibrillary tangles years before clinical symptoms manifest. Under the National Institute on Aging and Alzheimer's Association research framework, positive biomarker status defines Alzheimer's disease biologically rather than syndromically. However, clinicians and researchers tend to emphasize that biological detection does not necessarily indicate immediate cognitive deterioration. Long-term prospective data suggest that a substantial proportion of amyloid-positive older adults may remain cognitively unimpaired throughout their natural lifespans.
The temporal relationship between protein aggregation and symptomatic onset remains arguably one of the most debated questions in modern neurology.